FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040548891> ?p ?o ?g. }

• W2040548891 endingPage "1300" @default.
• W2040548891 startingPage "1293" @default.
• W2040548891 abstract "The purpose of this randomized trial was to compare the efficacy of 6 cycles of prednisolone, Adriamycin (doxorubicin), bleomycin, vincristine (Oncovin) and etoposide (PABlOE) with 3 cycles of PABIOE that alternate with 3 cycles of chlorambucil, vinblastine, procarbazine and prednisone (ChlVPP) in patients with advanced Hodgkin's disease. Between October 1992 and April 1996, 679 patients were entered onto the study. 41 of these did not match the protocol requirements on review and were excluded from further analysis, most of these being reclassified as NHL on histological review. Of the remaining 638 patients, 319 were allocated to receive PABIOE and 319 were allocated to receive ChlVPP/PABlOE. The complete remission (CR) rates were 78% and 64%, for ChlVPP/PABlOE and PABIOE respectively after initial chemotherapy (P< 0.0001). 124 patients were re-evaluated subsequently following radiotherapy to residual masses. The CR rates changed from 78% to 88% for ChlVPP/PABlOE and from 64% to 77% for PABlOE when re-evaluated in this manner (treatment difference still significant P = 0.0002). The treatment associated mortality in the PABlOE arm was 2.2% (7 deaths), while there were no such deaths in the ChlVPP/PABlOE arm (P = 0.015). The failure-free survival was significantly greater in the ChlVPP/PABlOE arm (P< 0.0001) as was the overall survival (P = 0.01). The failure-free and overall survival rates at 3 years were 77% and 91% in the ChlVPP/PABlOE arm, compared with 58% and 85% in the PABIOE arm, respectively. These results indicate that ChlVPP alternating with PABIOE is superior to PABIOE alone as initial treatment for advanced Hodgkin's disease. © 2001 Cancer Research Campaign" @default.
• W2040548891 created "2016-06-24" @default.
• W2040548891 creator A5008035303 @default.
• W2040548891 creator A5011583707 @default.
• W2040548891 creator A5020889052 @default.
• W2040548891 creator A5024050303 @default.
• W2040548891 creator A5036848123 @default.
• W2040548891 creator A5054834592 @default.
• W2040548891 creator A5066371033 @default.
• W2040548891 creator A5067838760 @default.
• W2040548891 creator A5082102746 @default.
• W2040548891 creator A5085292877 @default.
• W2040548891 creator A5086212361 @default.
• W2040548891 date "2001-01-01" @default.
• W2040548891 modified "2023-10-07" @default.
• W2040548891 title "ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial" @default.
• W2040548891 cites W102063770 @default.
• W2040548891 cites W1808994586 @default.
• W2040548891 cites W1825210192 @default.
• W2040548891 cites W1827683443 @default.
• W2040548891 cites W1865367030 @default.
• W2040548891 cites W1867518193 @default.
• W2040548891 cites W1880639950 @default.
• W2040548891 cites W1905906989 @default.
• W2040548891 cites W1911120442 @default.
• W2040548891 cites W1949980229 @default.
• W2040548891 cites W1969076048 @default.
• W2040548891 cites W1970700482 @default.
• W2040548891 cites W1999147615 @default.
• W2040548891 cites W2038252730 @default.
• W2040548891 cites W2055310422 @default.
• W2040548891 cites W2065065060 @default.
• W2040548891 cites W2092015388 @default.
• W2040548891 cites W2092304092 @default.
• W2040548891 cites W2165308914 @default.
• W2040548891 cites W2185580724 @default.
• W2040548891 cites W2255027144 @default.
• W2040548891 cites W2328232339 @default.
• W2040548891 cites W2413853954 @default.
• W2040548891 cites W2442716094 @default.
• W2040548891 doi "https://doi.org/10.1054/bjoc.2001.1778" @default.
• W2040548891 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2363648" @default.
• W2040548891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11355937" @default.
• W2040548891 hasPublicationYear "2001" @default.
• W2040548891 type Work @default.
• W2040548891 sameAs 2040548891 @default.
• W2040548891 citedByCount "22" @default.
• W2040548891 countsByYear W20405488912012 @default.
• W2040548891 countsByYear W20405488912014 @default.
• W2040548891 countsByYear W20405488912017 @default.
• W2040548891 countsByYear W20405488912020 @default.
• W2040548891 crossrefType "journal-article" @default.
• W2040548891 hasAuthorship W2040548891A5008035303 @default.
• W2040548891 hasAuthorship W2040548891A5011583707 @default.
• W2040548891 hasAuthorship W2040548891A5020889052 @default.
• W2040548891 hasAuthorship W2040548891A5024050303 @default.
• W2040548891 hasAuthorship W2040548891A5036848123 @default.
• W2040548891 hasAuthorship W2040548891A5054834592 @default.
• W2040548891 hasAuthorship W2040548891A5066371033 @default.
• W2040548891 hasAuthorship W2040548891A5067838760 @default.
• W2040548891 hasAuthorship W2040548891A5082102746 @default.
• W2040548891 hasAuthorship W2040548891A5085292877 @default.
• W2040548891 hasAuthorship W2040548891A5086212361 @default.
• W2040548891 hasBestOaLocation W20405488911 @default.
• W2040548891 hasConcept C126322002 @default.
• W2040548891 hasConcept C141071460 @default.
• W2040548891 hasConcept C168563851 @default.
• W2040548891 hasConcept C2776232574 @default.
• W2040548891 hasConcept C2776694085 @default.
• W2040548891 hasConcept C2776715498 @default.
• W2040548891 hasConcept C2776755627 @default.
• W2040548891 hasConcept C2777132456 @default.
• W2040548891 hasConcept C2777866208 @default.
• W2040548891 hasConcept C2778119113 @default.
• W2040548891 hasConcept C2778720950 @default.
• W2040548891 hasConcept C2779112685 @default.
• W2040548891 hasConcept C2779429289 @default.
• W2040548891 hasConcept C2779434656 @default.
• W2040548891 hasConcept C71924100 @default.
• W2040548891 hasConcept C90924648 @default.
• W2040548891 hasConceptScore W2040548891C126322002 @default.
• W2040548891 hasConceptScore W2040548891C141071460 @default.
• W2040548891 hasConceptScore W2040548891C168563851 @default.
• W2040548891 hasConceptScore W2040548891C2776232574 @default.
• W2040548891 hasConceptScore W2040548891C2776694085 @default.
• W2040548891 hasConceptScore W2040548891C2776715498 @default.
• W2040548891 hasConceptScore W2040548891C2776755627 @default.
• W2040548891 hasConceptScore W2040548891C2777132456 @default.
• W2040548891 hasConceptScore W2040548891C2777866208 @default.
• W2040548891 hasConceptScore W2040548891C2778119113 @default.
• W2040548891 hasConceptScore W2040548891C2778720950 @default.
• W2040548891 hasConceptScore W2040548891C2779112685 @default.
• W2040548891 hasConceptScore W2040548891C2779429289 @default.
• W2040548891 hasConceptScore W2040548891C2779434656 @default.
• W2040548891 hasConceptScore W2040548891C71924100 @default.
• W2040548891 hasConceptScore W2040548891C90924648 @default.
• W2040548891 hasIssue "10" @default.
• W2040548891 hasLocation W20405488911 @default.

• next